These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 36640215)

  • 41. Clinical and multimodality imaging results at 6 months of a bioresorbable sirolimus-eluting scaffold for patients with single de novo coronary artery lesions: the NeoVas first-in-man trial.
    Zhang YJ; Wang XZ; Fu G; Jing QM; Wang G; Jin CY; Xie LH; Cai JZ; Xu B; Han YL
    EuroIntervention; 2016 Nov; 12(10):1279-1287. PubMed ID: 27866137
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Scaffold and edge vascular response following implantation of everolimus-eluting bioresorbable vascular scaffold: a 3-year serial optical coherence tomography study.
    Zhang YJ; Iqbal J; Nakatani S; Bourantas CV; Campos CM; Ishibashi Y; Cho YK; Veldhof S; Wang J; Onuma Y; Garcia-Garcia HM; Dudek D; van Geuns RJ; Serruys PW;
    JACC Cardiovasc Interv; 2014 Dec; 7(12):1361-9. PubMed ID: 25457053
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Two year efficacy and safety of small versus large ABSORB bioresorbable vascular scaffolds of ≤18 mm device length: A subgroup analysis of the German-Austrian ABSORB RegIstRy (GABI-R).
    Zaczkiewicz M; Wein B; Graf M; Zimmermann O; Kastner J; Wöhrle J; Thomas R; Hamm C; Torzewski J;
    Int J Cardiol Heart Vasc; 2020 Apr; 27():100501. PubMed ID: 32258361
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Scaffold underexpansion and late lumen loss after bioresorbable scaffold implantation: Insights from ABSORB JAPAN trial.
    Okada K; Honda Y; Kitahara H; Ikutomi M; Kameda R; Brooke Hollak M; Yock PG; Popma JJ; Kusano H; Cheong WF; Sudhir K; Fitzgerald PJ; Kimura T;
    Int J Cardiol Heart Vasc; 2020 Dec; 31():100623. PubMed ID: 32944608
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Randomized Comparison of Absorb Bioresorbable Vascular Scaffold and Mirage Microfiber Sirolimus-Eluting Scaffold Using Multimodality Imaging.
    Tenekecioglu E; Serruys PW; Onuma Y; Costa R; Chamié D; Sotomi Y; Yu TB; Abizaid A; Liew HB; Santoso T
    JACC Cardiovasc Interv; 2017 Jun; 10(11):1115-1130. PubMed ID: 28527768
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Comparison of everolimus-eluting and biolimus-eluting coronary stents with everolimus-eluting bioresorbable scaffold: study protocol of the randomized controlled EVERBIO II trial.
    Arroyo D; Togni M; Puricel S; Gerard B; Sonja L; Corpataux N; Villeneuve H; Boute E; Stauffer JC; Goy JJ; Cook S
    Trials; 2014 Jan; 15():9. PubMed ID: 24398143
    [TBL] [Abstract][Full Text] [Related]  

  • 47. The Cone Flare Crush Modified-T (CFCT) stenting technique for coronary artery bifurcation lesions.
    Peverill WT; Incani A; Worthley SG; Singbal Y; Garrahy PJ; McCann AB; Cox SV; Moore PT; Lim RYY; Fetahovic T; Connors GW; Hall C; Sieg C; Camuglia AC
    Int J Cardiol Heart Vasc; 2020 Oct; 30():100643. PubMed ID: 33015315
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Magnesium-Based Resorbable Scaffold Versus Permanent Metallic Sirolimus-Eluting Stent in Patients With ST-Segment Elevation Myocardial Infarction: The MAGSTEMI Randomized Clinical Trial.
    Sabaté M; Alfonso F; Cequier A; Romaní S; Bordes P; Serra A; Iñiguez A; Salinas P; García Del Blanco B; Goicolea J; Hernández-Antolín R; Cuesta J; Gómez-Hospital JA; Ortega-Paz L; Gomez-Lara J; Brugaletta S
    Circulation; 2019 Dec; 140(23):1904-1916. PubMed ID: 31553204
    [TBL] [Abstract][Full Text] [Related]  

  • 49. [The safety and efficacy of Firesorb bioresorbable scaffold in first-in-man study for coronary artery disease: the four-year outcomes].
    Li CJ; Xu B; Song L; Yu MY; Yan HB; Qiu H; Mu CW; Cui JG; Guan CD; Sun ZW; Qiao SB; Gao RL
    Zhonghua Xin Xue Guan Bing Za Zhi; 2021 Feb; 49(2):128-135. PubMed ID: 33611898
    [No Abstract]   [Full Text] [Related]  

  • 50. Routine use of optical coherence tomography in bioresorbable vascular scaffold implantation: insights on technique optimization and long-term outcomes.
    Abdelaziz HK; Abuomara HZ; Ali MH; Eichhofer J; Patel B; Saad M
    Coron Artery Dis; 2019 Jun; 30(4):263-269. PubMed ID: 30883433
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Six-month outcomes of the XINSORB bioresorbable sirolimus-eluting scaffold in treating single de novo lesions in human coronary artery.
    Wu Y; Shen L; Ge L; Wang Q; Qian J; Zhang F; Yao K; Huang D; Chen Y; Ge J
    Catheter Cardiovasc Interv; 2016 Mar; 87 Suppl 1():630-7. PubMed ID: 26864162
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Two-year clinical, angiographic, and serial optical coherence tomographic follow-up after implantation of an everolimus-eluting bioresorbable scaffold and an everolimus-eluting metallic stent: insights from the randomised ABSORB Japan trial.
    Onuma Y; Sotomi Y; Shiomi H; Ozaki Y; Namiki A; Yasuda S; Ueno T; Ando K; Furuya J; Igarashi K; Kozuma K; Tanabe K; Kusano H; Rapoza R; Popma JJ; Stone GW; Simonton C; Serruys PW; Kimura T
    EuroIntervention; 2016 Oct; 12(9):1090-1101. PubMed ID: 27597270
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Outcome of everolimus eluting bioabsorbable vascular scaffold (BVS) compared to non BVS drug eluting stent in the management of ST-segment elevation myocardial infarction (STEMI) - A comparative study.
    Chakraborty R; Patra S; Banerjee S; Pande A; Khan A; Mandol PC; Ghosh D; De SK; Das SS; Nag R
    Cardiovasc Revasc Med; 2016; 17(3):151-4. PubMed ID: 26905052
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Evaluation of the second generation of a bioresorbable everolimus-eluting vascular scaffold for the treatment of de novo coronary artery stenosis: 12-month clinical and imaging outcomes.
    Serruys PW; Onuma Y; Dudek D; Smits PC; Koolen J; Chevalier B; de Bruyne B; Thuesen L; McClean D; van Geuns RJ; Windecker S; Whitbourn R; Meredith I; Dorange C; Veldhof S; Hebert KM; Sudhir K; Garcia-Garcia HM; Ormiston JA
    J Am Coll Cardiol; 2011 Oct; 58(15):1578-88. PubMed ID: 21958884
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Implantation of bioresorbable scaffolds under guidance of optical coherence tomography: Feasibility and pilot clinical results of a systematic protocol.
    Gutiérrez-Chico JL; Cortés C; Schincariol M; Limon U; Yalcinli M; Durán-Cortés MA; Jaguszewski M
    Cardiol J; 2018; 25(4):443-458. PubMed ID: 29774520
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Randomized Comparison Between Everolimus-Eluting Bioresorbable Scaffold and Metallic Stent: Multimodality Imaging Through 3 Years.
    Onuma Y; Honda Y; Asano T; Shiomi H; Kozuma K; Ozaki Y; Namiki A; Yasuda S; Ueno T; Ando K; Furuya J; Hanaoka KI; Tanabe K; Okada K; Kitahara H; Ono M; Kusano H; Rapoza R; Simonton C; Popma JJ; Stone GW; Fitzgerald PJ; Serruys PW; Kimura T
    JACC Cardiovasc Interv; 2020 Jan; 13(1):116-127. PubMed ID: 31918929
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Optical Coherence Tomography-Guided Percutaneous Coronary Intervention for ST-Segment Elevation Myocardial Infarction: Rationale and Design of the ATLAS-OCT Study.
    Yonetsu T; Wakabayashi K; Mizukami T; Yamamoto MH; Yasuhara S; Kondo S; Oishi Y; Okabe T; Sugiyama T; Araki M; Takano M; Kobayashi N; Kimura S; Yamakami Y; Suwa S; Nakamura S; Mitomo S; Kakuta T; Usui E; Higuma T; Ako J; Minami Y; Iwasaki M; Shite J; Kozuki A; Saito S; Shishido K; Okura H; Naruse G; Uemura S; Kume T; Nanasato M; Dohi T; Ashikaga T; Otake H; Mori H; Sekimoto T; Sugizaki Y; Shinke T;
    Am J Cardiol; 2023 Sep; 203():466-472. PubMed ID: 37562073
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Early and late optical coherence tomography findings following everolimus-eluting bioresorbable vascular scaffold implantation in myocardial infarction: a preliminary report.
    Karanasos A; Muramatsu T; Diletti R; Nauta S; Onuma Y; Lenzen M; Nakatani S; Van Mieghem NM; Schultz C; De Jaegere PP; Serruys PW; Zijlstra F; Regar E; van Geuns RJ
    Hellenic J Cardiol; 2015; 56(2):125-35. PubMed ID: 25854441
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Serial invasive imaging follow-up of the first clinical experience with the Magmaris magnesium bioresorbable scaffold.
    Tovar Forero MN; van Zandvoort L; Masdjedi K; Diletti R; Wilschut J; de Jaegere PP; Zijlstra F; Van Mieghem NM; Daemen J
    Catheter Cardiovasc Interv; 2020 Feb; 95(2):226-231. PubMed ID: 31033171
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Optical coherence tomography-guided versus angiography-guided implantation of everolimus-eluting bioresorbable vascular scaffolds: Comparison of coverage, apposition and clinical outcome. The ALSTER-OCT ABSORB registry.
    Heeger CH; Schedifka AS; Meincke F; Spangenberg T; Wienemann H; Kreidel F; Kuck KH; Ghanem A; Bergmann MW
    Cardiol J; 2018; 25(4):459-469. PubMed ID: 29512092
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.